Prevalence and genomic insights into type III-A CRISPR-Cas system acquisition in global Staphylococcus argenteus strains
Frontiers in Cellular and Infection Microbiology · 2025
DOI: 10.3389/fcimb.2025.1644286 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Xinhai Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Lab of Zoonosis/Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou Un…. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Staphylococcus, Genome, Bacterial, Staphylococcal Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The CRISPR-Cas system serves as a defense mechanism in bacteria and archaea, protecting them against the invasion of mobile genetic elements. Staphylococcus argenteus , a Gram-positive bacterium that diverged from Staphylococcus aureus , is characterized by the rare presence of the CRISPR-Cas system in only a few isolates.
Methods
In this study, we analyzed the prevalence of the type III-A CRISPR-Cas system in 368 S. argenteus genome sequences from animals, food sources, and humans across 26 countries, available in public database.
Results
Our findings revealed that 44.0% of these strains carry this immune system, with 98.1% of them belonging to the sequence type 2250 (ST2250). Genomic localization analysis indicated that the CRISPR-Cas is closely associated with SCCmec ( mecA-ΔmecR1-IS1272-ccrB2-ccrA2 ) or Insertion sequence 1272 (IS 1272 ) transposase. Further analysis identified a common IS 1272 target inverted repeats (IR) sequence in ST2250 strains, providing insights into why these strains are more likely to acquire the CRISPR-Cas system. CRISPR typing identified 41 sequences types, classifying these strains into two clusters, with Cluster II being the predominant one. Homology analysis of spacers revealed that all the identified 15 spacers exhibited homology to sequences from plasmids, lytic phages, or prophages.
Conclusion
This study suggests that the acquisition of the CRISPR-Cas system in S. argenteus enhances its resistance to phage attacks and plasmid invasions in environmental settings, potentially posing significant challenges for clinical treatment of infections caused by these strains and hindering efforts to control their spread in food products using phage-based interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Lab of Zoonosis/Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou, China.
- Joint International Research Laboratory of Agriculture and Agri-Product Safety, Yangzhou University, Yangzhou, China.
- Key Laboratory of Prevention and Control of Biological Hazard Factors (Animal Origin) for Agri-food Safety and Quality, Ministry of Agriculture of China, Yangzhou University, Yangzhou, China.
Zitieren
APA
Chen, X., Xu, L., Luo, Z., Wang, L., Wang, Z., Li, Y., Jiao, X., & Li, Q. (2025). Prevalence and genomic insights into type III-A CRISPR-Cas system acquisition in global Staphylococcus argenteus strains. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1644286
Vancouver
Chen X, Xu L, Luo Z, Wang L, Wang Z, Li Y, et al. Prevalence and genomic insights into type III-A CRISPR-Cas system acquisition in global Staphylococcus argenteus strains. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2025.1644286
BibTeX
@article{Chen2025,
author = {Chen, Xinhai and Xu, Li and Luo, Zhijiang and Wang, Lihong and Wang, Zhenyu and Li, Yang and Jiao, Xinan and Li, Qiuchun},
title = {Prevalence and genomic insights into type III-A CRISPR-Cas system acquisition in global Staphylococcus argenteus strains},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
doi = {10.3389/fcimb.2025.1644286}
}
EUVIMED